Does Depakote (valproic acid) improve dementia symptoms, specifically vocalizations or calling out?

Depakote Does Not Help with Dementia-Related Calling Out and Should Not Be Used

Depakote (valproic acid) is probably ineffective for treating agitation and vocalizations in dementia and is associated with higher rates of adverse effects, including sedation, gastrointestinal symptoms, and serious adverse events. Based on the strongest available evidence, valproate should not be used for managing behavioral symptoms like calling out in people with dementia 1.

Evidence Against Valproate Use

The highest quality evidence comes from a 2018 Cochrane systematic review analyzing five randomized controlled trials with 430 participants 1. This meta-analysis found:

• No reduction in agitation: Moderate-quality evidence from two studies measuring the Brief Psychiatric Rating Scale (BPRS) showed no benefit over six weeks (mean difference 0.23,95% CI -2.14 to 2.59)
• Increased adverse effects: Valproate-treated participants had twice the odds of experiencing adverse effects (OR 2.02,95% CI 1.30 to 3.14)
• Possible increase in serious adverse events: Very low-quality evidence suggested nearly 5 times higher odds of serious adverse events (OR 4.77,95% CI 1.00 to 22.74)
• Worse functional ability: Moderate-quality evidence showed slightly worse function on the Physical Self-Maintenance Scale in valproate-treated patients

Specific Safety Concerns in Elderly Dementia Patients

The FDA drug label specifically warns about somnolence in elderly patients with dementia 2. In a double-blind trial of elderly dementia patients (mean age 83 years):

• Significantly higher proportion experienced somnolence compared to placebo
• Higher rates of dehydration
• Reduced nutritional intake and weight loss in approximately half of somnolent patients
• Higher discontinuation rates due to somnolence

The FDA label explicitly states that in elderly patients, dosage should be increased slowly with regular monitoring for fluid and nutritional intake, dehydration, and somnolence, with consideration for dose reduction or discontinuation 2.

Contradictory Lower-Quality Evidence

While some older, small, uncontrolled studies from the 1990s suggested potential benefit 3, 4, and recent retrospective data from Asia showed 62% response rates 5, these findings are contradicted by the higher-quality placebo-controlled trials. The Cochrane review specifically notes that uncontrolled trials showed apparent benefits while controlled trials did not 1.

One retrospective study suggested valproate at low doses (serum levels 40-60 mcg/mL) might help agitation without psychosis, but noted it had limited efficacy as monotherapy 6. However, this conflicts with the controlled trial evidence.

Clinical Bottom Line

Do not prescribe Depakote for calling out or other behavioral symptoms in dementia. The evidence shows:

1. Lack of efficacy: Probably no benefit for agitation or vocalizations
2. Significant harm: Higher risk of sedation, falls, dehydration, reduced food intake, gastrointestinal symptoms, and urinary tract infections
3. Vulnerable population: Elderly dementia patients are particularly susceptible to adverse effects

Alternative Approach

Instead of valproate, prioritize:

• Non-pharmacological interventions first (as recommended by expert consensus 7)
• Rule out underlying causes: pain, infection, constipation, medication side effects, environmental triggers
• If medication is absolutely necessary after non-pharmacological approaches fail, consider other options with better evidence (though all psychotropics carry risks in this population)

The Cochrane review concludes that "valproate therapy cannot be recommended for management of agitation in dementia" and questions whether further research is even justified given the increased risk of adverse effects 1.